General Information of Drug (ID: DMCM0K6)

Drug Name
YPEG-Somatropin Drug Info
Synonyms YPEG-Somatropin (growth hormone deficiency)
Indication
Disease Entry ICD 11 Status REF
Growth hormone deficiency 5A61.3 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMCM0K6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Somatotropin (GH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lonapegsomatropin DMPR8E9 Growth failure LD2F.1Y Approved [3]
HGH-CTP DMXAZ47 Growth hormone deficiency 5A61.3 Phase 3 [4]
Albutropin DMWAL73 Growth failure LD2F.1Y Phase 3 [5]
VRS-317 DMWMT5N Growth hormone deficiency 5A61.3 Phase 3 [6]
Somatropin intranasal rhGH DMK3RL8 Growth hormone deficiency 5A61.3 Phase 2 [7]
ARX-201 DMS0LCZ Growth failure LD2F.1Y Discontinued in Phase 2 [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatotropin (GH1) TTT3YKH SOMA_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01339182) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers. U.S. National Institutes of Health.
2 Somatropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol. 2004;3(3):153-60.
3 ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health.
4 Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538.
5 Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58.
6 Company report (Versartis)
7 Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20.
8 Company report (Avarx)